Gyre Therapeutics (GYRE) Competitors $7.26 -0.16 (-2.09%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GYRE vs. APLS, KNSA, MOR, IMVT, HCM, OGN, MLYS, TARS, ALVO, and CDTXShould you be buying Gyre Therapeutics stock or one of its competitors? The main competitors of Gyre Therapeutics include Apellis Pharmaceuticals (APLS), Kiniksa Pharmaceuticals International (KNSA), MorphoSys (MOR), Immunovant (IMVT), HUTCHMED (HCM), Organon & Co. (OGN), Mineralys Therapeutics (MLYS), Tarsus Pharmaceuticals (TARS), Alvotech (ALVO), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Gyre Therapeutics vs. Its Competitors Apellis Pharmaceuticals Kiniksa Pharmaceuticals International MorphoSys Immunovant HUTCHMED Organon & Co. Mineralys Therapeutics Tarsus Pharmaceuticals Alvotech Cidara Therapeutics Gyre Therapeutics (NASDAQ:GYRE) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Which has preferable valuation and earnings, GYRE or APLS? Gyre Therapeutics has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M6.61$12.09M$0.01725.50Apellis Pharmaceuticals$781.37M3.89-$197.88M-$1.82-13.22 Is GYRE or APLS more profitable? Gyre Therapeutics has a net margin of 4.08% compared to Apellis Pharmaceuticals' net margin of -30.24%. Gyre Therapeutics' return on equity of 7.67% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics4.08% 7.67% 6.19% Apellis Pharmaceuticals -30.24%-116.09%-26.72% Do analysts recommend GYRE or APLS? Gyre Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 148.10%. Apellis Pharmaceuticals has a consensus target price of $33.29, suggesting a potential upside of 38.33%. Given Gyre Therapeutics' higher probable upside, equities research analysts clearly believe Gyre Therapeutics is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Apellis Pharmaceuticals 2 Sell rating(s) 8 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.45 Do institutionals and insiders hold more shares of GYRE or APLS? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, GYRE or APLS? Gyre Therapeutics has a beta of 1.78, meaning that its share price is 78% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Does the media refer more to GYRE or APLS? In the previous week, Apellis Pharmaceuticals had 8 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Apellis Pharmaceuticals and 0 mentions for Gyre Therapeutics. Apellis Pharmaceuticals' average media sentiment score of 0.31 beat Gyre Therapeutics' score of 0.00 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Gyre Therapeutics Neutral Apellis Pharmaceuticals Neutral SummaryGyre Therapeutics beats Apellis Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Gyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GYRE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GYRE vs. The Competition Export to ExcelMetricGyre TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$698.73M$3.36B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio726.2322.2286.0827.08Price / Sales6.61268.80534.29204.46Price / Cash37.5246.3226.3031.09Price / Book6.919.9712.726.66Net Income$12.09M-$52.35M$3.30B$275.86M7 Day Performance-3.27%6.36%4.34%3.06%1 Month Performance-5.66%12.02%7.82%10.52%1 Year Performance-46.14%26.08%73.82%33.54% Gyre Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GYREGyre Therapeutics1.1488 of 5 stars$7.26-2.1%$18.00+148.1%-45.0%$698.73M$105.76M726.2340APLSApellis Pharmaceuticals4.2018 of 5 stars$22.67+0.1%$33.29+46.9%-13.5%$2.86B$781.37M-12.44770KNSAKiniksa Pharmaceuticals International3.7073 of 5 stars$38.59-0.5%$44.29+14.8%+57.2%$2.86B$423.24M965.04220Analyst DowngradeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730IMVTImmunovant1.8974 of 5 stars$15.99-0.4%$33.20+107.6%-44.6%$2.79BN/A-5.61120HCMHUTCHMED2.4526 of 5 stars$15.86+1.2%$20.88+31.7%-23.4%$2.77B$630.20M0.001,811OGNOrganon & Co.4.7938 of 5 stars$10.38+0.2%$17.33+67.1%-39.7%$2.70B$6.40B3.864,000Positive NewsMLYSMineralys Therapeutics2.9723 of 5 stars$39.54+0.5%$43.50+10.0%+174.2%$2.62BN/A-11.0828TARSTarsus Pharmaceuticals0.4905 of 5 stars$59.32+2.1%$66.67+12.4%+92.3%$2.49B$182.95M-25.3650Gap UpALVOAlvotech3.153 of 5 stars$8.19-2.6%$14.00+71.0%-32.4%$2.47B$560.10M35.591,032CDTXCidara Therapeutics3.9655 of 5 stars$96.92+1.7%$119.43+23.2%+835.7%$2.46B$1.27M-8.7290Analyst Forecast Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Kiniksa Pharmaceuticals International Competitors MorphoSys Competitors Immunovant Competitors HUTCHMED Competitors Organon & Co. Competitors Mineralys Therapeutics Competitors Tarsus Pharmaceuticals Competitors Alvotech Competitors Cidara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GYRE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
